EFPIA and Innovative Medicines Initiative announce new projects to fight Ebola

16 January 2015

The European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Innovative Medicines Initiative have announced eight new projects which will be launched as part of the Ebola+ program.

The projects aim to address the needs of the current epidemic, including development of a new vaccine, its production and distribution, and new diagnostics that can be used at the point of care. They will form the first step of the Ebola+ program, which has a budget of 215 million euros ($249 million).

The announcement comes days before the 2015 World Economic Forum in Davos, which will include a discussion on global health security inspired by the latest battle with Ebola.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK